Richard J. Barry's most recent trade in Sarepta Therapeutics Inc was a trade of 12,350 Common Stock done at an average price of $32.6 . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.63 per share. | 16 May 2025 | 12,350 | 2,966,667 (3%) | 0% | 32.6 | 402,981 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 12,350 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 10,500 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.71 per share. | 13 May 2025 | 10,500 | 2,954,317 (3%) | 0% | 13.7 | 143,955 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.18 per share. | 13 May 2025 | 9,746 | 2,943,817 (3%) | 0% | 25.2 | 245,404 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 9,746 | 0 | - | - | Stock Option (right to buy) | |
| Cassava Sciences Inc | Richard J. Barry | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2025 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 4,792 | 4,792 | - | - | Stock Options (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 2,383 | 2,934,071 (3%) | 0% | 0 | Common Stock | |
| Cassava Sciences Inc | Richard J. Barry | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Cassava Sciences Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Cassava Sciences Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.00 per share. | 23 Apr 2024 | 176,085 | 469,562 (2%) | 1% | 22 | 3,873,870 | Common Stock |
| Cassava Sciences Inc | Richard J. Barry | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2024 | 117,390 | 0 | - | - | Common Stock Warrant | |
| Cassava Sciences Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2024 | 117,390 | 176,085 | - | - | Common Stock Warrant | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,679 | 3,679 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 1,846 | 2,931,688 (3%) | 0% | 0 | Common Stock | |
| Cassava Sciences Inc | Richard J. Barry | Director | Purchase of securities on an exchange or from another person at price $ 16.65 per share. | 21 Aug 2023 | 16,571 | 293,477 (1%) | 0% | 16.6 | 275,907 | Common Stock |
| Cassava Sciences Inc | Richard J. Barry | Director | Purchase of securities on an exchange or from another person at price $ 16.80 per share. | 21 Aug 2023 | 1,906 | 276,906 (1%) | 0% | 16.8 | 32,021 | Common Stock |
| Cassava Sciences Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 20,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Cassava Sciences Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Cassava Sciences Inc | Richard J. Barry | Director | Purchase of securities on an exchange or from another person at price $ 25.76 per share. | 06 Mar 2023 | 77,276 | 275,000 (1%) | 0% | 25.8 | 1,990,630 | Common Stock |
| Cassava Sciences Inc | Richard J. Barry | Director | Purchase of securities on an exchange or from another person at price $ 26.13 per share. | 06 Mar 2023 | 11,565 | 197,724 (1%) | 0% | 26.1 | 302,193 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 3,257 | 3,257 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 1,523 | 2,929,842 (3%) | 0% | 0 | Common Stock | |
| Cassava Sciences Inc | Richard J. Barry | Director | Purchase of securities on an exchange or from another person at price $ 23.79 per share. | 23 Aug 2022 | 36,159 | 186,159 (1%) | 0% | 23.8 | 860,223 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 5,077 | 5,077 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 2,953 | 2,928,319 (3%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 5,518 | 5,518 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 2,726 | 3,125,366 (4%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Sale of securities on an exchange or to another person at price $ 158.43 per share. | 07 Aug 2020 | 26,860 | 3,132,280 (4%) | 0% | 158.4 | 4,255,430 | Common Stock |
| Sarepta Therapeutics Inc | Richard J. Barry | Director | Sale of securities on an exchange or to another person at price $ 159.09 per share. | 07 Aug 2020 | 3,140 | 3,129,140 (4%) | 0% | 159.1 | 499,543 | Common Stock |
| Mimedx Group Inc | Richard J. Barry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 38,135 | 3,338,135 (3%) | 0% | 0 | Common Stock |